Generics 40

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Irinotecan manufacturers

40 products found

Filters

40 products found

irinotecan

Concentrate for solution for infusion 40 mg, 100 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
South Africa
MAs for sale
Canada
Manufacturer #6301
A pharmaceutical manufacturer based in the EU that has been active in 50+ countries selling its products in Europe, MENA, LATAM, and NA for 20+ years. Main therapeutic area include oncology and urology. The company's production lines are GMP-compliant. The main dosage forms includes injectable. The company possesses subsidiaries in LATAM

Manufacturer usually replies in 3 days

irinotecan

Solution for infusion 20mg/ml - 2 ml, 5 ml, 15 ml, 25 ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #614
A pharmaceutical manufacturer based in Europe selling its products in Europe and worldwide for 10+ years. Main dosage forms include injectable and oral dosage forms. The company's production lines are EU GMP-compliant. The main therapeutic area is oncology.

Manufacturer usually replies in 7 days

irinotecan

Concentrate for solution for infusion 40mg, 100mg, 300mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
FDA, EU GMP
Unavailable markets
Egypt , Lebanon , Algeria , Bahrain , Kuwait , Oman , Qatar , Saudi Arabia , United Arab Emirates , Iran , Iraq , Israel , Jordan , Libya , Morocco , Sudan , Syria , Tunisia , Yemen
Manufacturer #8191
A pharmaceutical manufacturer based in Europe that has been active in 10+ countries selling its products in Europe, North America, Asia, MENA, and LATAM for 10+ years. The main therapeutic areas include oncology and immunology. The company's production lines are GMP-compliant. The company possesses branches in Europe and MENA.

Manufacturer usually replies in 9 days

irinotecan

Injection 4.3 mg/ml

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #11907
A pharmaceutical manufacturer based in the EU that is active in 40+ countries selling its products for 20+ years. Key production lines include Rx, OTC, medical devices, and cosmetics. The company's production lines are EU GMP-compliant. The company owns branches in the EU, North America, and Africa.

Manufacturer usually replies in 8 days

irinotecan

Concentrate for solution for infusion 40 mg/2 ml, 100 mg/5 ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Kosovo
Manufacturer #298

Manufacturer usually replies in 3 days

irinotecan

Solution for infusion 40mg/2ml 100mg/5ml 300mg/15ml 500mg/25ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
China
GMP approvals
EU GMP
Unavailable markets
United Kingdom
Manufacturer #9300

Manufacturer usually replies in 3 days

irinotecan

Solution for injection 20 mg/ml - 2 ml, 5 ml, 15 ml, 25 ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Unavailable markets
Costa Rica
Registered in
Austria , France , Ireland , Malta , Romania
Manufacturer #1338

Manufacturer usually replies in 7 days

irinotecan

Concentrate for solution for infusion 40 mg/2 ml , 100 mg/5 ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Unavailable markets
Chile , Turkey , Vietnam , Panama
Available for
Licensing with supply
Manufacturer #261
A pharmaceutical manufacturer based in the EU that has been selling its products in Europe for 20+ years. Main therapeutic areas include diabetes, CNL, dermatology, and oncology. Main dosage forms include solid and liquid oral, sterile dosage forms, and ointments. The company possesses 10+ manufacturing facilities that are cGMP-compliant.

Manufacturer usually replies in 6 days

irinotecan

Injection 100 mg/5 ml, 300 mg/15 ml, 40 mg/2 ml, 500 mg/25 ml,

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Manufacturer #15176

Manufacturer usually replies in 5 days

irinotecan

Vials, injection 40 mg/2 ml, 100 mg/5 ml, 300 mg/15ml, 500 mg/25 ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Turkey
GMP approvals
EU GMP
Manufacturer #2722
It originally entered the pharmaceutical industry in 1987, when it introduced blood derivative products to Europe and became the exclusive distributor for prominent European brands. Oncology, hematology, dermatology, radiology, rheumatology, immunology, and OTC products are the seven main therapeutic fields.

Manufacturer usually replies in 6 days

irinotecan

Solution for injection 40 mg/2 ml, 100 mg/5 ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
IN
Registered in
Chile , Cyprus , Dominican Republic , Ecuador , El Salvador , Ethiopia , Guatemala , Indonesia , Iraq , Israel , Kuwait , Malaysia , Mexico , Moldova , Morocco , Myanmar , Nicaragua , Panama , Paraguay , Peru , Philippines , Palestinian Territory , Senegal , Sri Lanka , Thailand , Trinidad And Tobago , Uganda , Ukraine , Venezuela , Vietnam , Yemen
Available for
Licensing with supply, Distribution only
Manufacturer #8924

Manufacturer usually replies in 9 days

irinotecan

Solution for infusion 20 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
PICS
Manufacturer #21567

Manufacturer usually replies in 2 days

irinotecan

Injection 40 mg, 100 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #20510

Manufacturer usually replies in 2 days

irinotecan

Solution for infusion 20 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Taiwan
GMP approvals
PICS
Manufacturer #20530
With the rapid improvement of pharmaceutical technology and the approaching aging society, they focus on the development of innovative healthcare technology for Acute and Critical Care and Anti-aging and Preventive Medicine. The company has passed US FDA, Japan PMDA, and PIC/S GMP inspections through specific approaches to total quality management.

Manufacturer usually replies in 2 days

irinotecan

Solution for injection 40mg, 100mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Available for
Licensing with supply, Distribution only
Manufacturer #15976

Manufacturer usually replies in 3 days

irinotecan

Concentrate for solution for infusion 20mg/ml, 2ml, 5ml in vials; pack size: 1

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Ukraine
GMP approvals
WHO
Manufacturer #9289
A pharmaceutical manufacturer based in Europe that has been active in 30+ countries selling its products in Europe, the Middle East, Africa, CIS, and Asia for 30+ years. The main therapeutic areas include gynecology, cardiology, urology, and antiviral. Key production lines are Rx Main dosage forms include solids, liquids, and injectables. The company's production lines are GMP-compliant.

Manufacturer usually replies in 4 days

irinotecan

Vials, injection 100mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Argentina
GMP approvals
PICS
Unavailable markets
Costa Rica
Manufacturer #678
It is situated in the southern part of South America. It is committed to excellence and continuous improvement. They have a production plant for the manufacturing of high value-added products like the treatment of HIV-AIDS and neurodegenerative and cardiovascular diseases.

Manufacturer usually replies in 3 days

irinotecan

Vials, injection 20 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Available for
Licensing with supply
Manufacturer #10323

Manufacturer usually replies in 5 days

irinotecan

Injection 400 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #18204

Manufacturer usually replies in 9 days

irinotecan

Vials, injection 40 mg, 100 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #17691

Manufacturer usually replies in 7 days

Want to view all 40 products? Create your free account today!

What is the Irinotecan drug?

Irinotecan is an antineoplastic enzyme inhibitor; it reduces the spread of the cancer cells in the body. It is a medication used to treat colon cancer and small cell lung cancer. Irinotecan is usually administered during chemotherapy as a single agent or in combination with other drugs.
The FDA, in the US, approved the medical use of Irinotecan medication in 1996. Irinotecan is on the WHO's List of Essential Medicines, the safest and most effective medicines needed in a health system. The natural compound camptothecin found in the Chineses ornamental tree Camptotheca acuminata is used to make the Irinotecan medication.

Irinotecan manufacturers and wholesalers:

The US brand name for Irinotecan is Camptosar. Irinotecan is a globally found drug. Among all the manufacturers, we can list some, such as Pfizer Inc, Accord Healthcare Inc, Actavis Totowa Llc, Teva Parenteral Medicines Inc, and Watson Laboratories Inc.
Irinotecan suppliers market it in the forms of 20 mg solutions or solutions for injection. Under the generic names, for injection of Irinotecan, the drug can be found at different dosages: 40 mg/2 ml; 100 mg/5 ml; 300 mg/15 ml; 500 mg/25 ml. For Camptosar, the solution for injection can be marketed in the strength of 40 mg/2 ml; 100 mg/5 ml; 300 mg/15 ml.

Irinotecan for sales:

On the US market, the price of Irinotecan can vary if it is sold under the generic name or the brand name. For 20mg/ml of an intravenous solution of Irinotecan, it can cost from $17 to $202 for 2ml, about $19.60 for 5ml, and about $131.30 for 25ml. The prices for Irinotecan under the brand name Camptosar are slightly different. For Camptosar 20 mg/ml intravenous solution, 2 ml costs about $35.60, 5 ml about $48.48, and for 15ml, it costs about $126.43
As Irinotecan is a globally found drug, you may encounter fraudulent online websites that will want to sell Irinotecan with some risks for you and your clients. By using Pipelinepharma B2B marketplace, you avoid time-consuming sourcing, and you directly find qualified sellers of Irinotecan. Those manufacturers and distributors have been through quality control procedures to ensure they were qualified partners. On the online platform, Irinotecan is mostly available from the EU, India, Argentina, Turkey, China, and Ukraine. Thanks to the intuitive online marketplace, you will find Irinotecan and many other drugs quickly and efficiently. Placing an order has never been easier than with Pipelinepharma. Let us connect you with Irinotecan. Manufacturers and distributors.

How to use Irinotecan drugs?

Using Irinotecan medication as a single agent for the treatment of colorectal cancer, an adult should be administered 125 mg/m2 IV over 90 minutes on Days 1, 8, 15, and 22 then 2-week rest or 350 mg/m2 IV over 90 minutes on Day 1 every three weeks.
Taking Irinotecan can cause some side effects, the most common ones are severe diarrhea, black, tarry stools, blood in the urine or stools, blurred vision, changes in skin color, and chest pain or discomfort.